Fundraising Fox
Claris Bio
Jersey City, US · Founded 2018 · 6 known investors
Find your way into Claris Bio
Sign up to see every warm intro you have to Claris Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Claris Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.
Founders & leadership
Claris Bio was founded in 2018 by Clarke Atwell.
CA
Clarke AtwellCo-Founder and Chief Operating OfficerClarke Atwell is co-founder and chief operating officer of Claris Bio, a company developing biologic therapies for sight-threatening eye diseases. He has held executive positions in biopharmaceutical companies with experience across product development, licensing, and commercialization.
HR
Henry RathExecutive
SO
Susan OrrChief Medical OfficerShe has held boardroom, leadership, and advisory roles focused on translating scientific innovation into commercial ventures.
SB
Stephen BradyNamed on SEC filing
MD
Michael DybbsNamed on SEC filing
MH
Matt HobsonNamed on SEC filing
MR
BB
Brian BaumNamed on SEC filing
Board
KH
MF
Meredith FisherBoard director
MD
Marc de GaridelBoard director
RD
Reza DanaBoard director
Investors · 6
Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M
How we know: funding news · Not right? Tell us
Catalio Capital ManagementreportedNew York
How we know: funding news · Not right? Tell us
Novo HoldingsreportedCopenhagen · $1.1M – $54M
How we know: funding news · fiercebiotech.com · Not right? Tell us
Samsara BioCapitalreportedMenlo Park
How we know: a partner's Signal profile · funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$233.8M disclosed across 6 of 8 rounds · 2020–2026
▶$55.7MraisedAug 2026 · 14 investors · BiotechnologyRule 506(b)
▶$55.7MraisedAug 2026 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen BradyExecutive Officer, Director
- Reza DanaDirector
- Kenneth HarrisonDirector
- Marc de GaridelDirector
- Meredith FisherDirector
- Henry RathExecutive Officer
- Susan OrrExecutive Officer
- Michael DybbsDirector
- Matt HobsonDirector
- Maha RadhakrishnanDirector
- Clarke AtwellExecutive Officer
- Brian BaumExecutive Officer
- Offering amount
- $121.5M
- Amount sold
- $55.7M
- Proceeds to insiders
- $3.1M
- First sale
- Nov 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedSep 2025 · 6 investors · BiotechnologyRule 506(b)
▶$2.3MraisedSep 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Meredith FisherDirector
- Reza DanaDirector
- Kenneth HarrisonDirector
- Henry RathExecutive Officer
- Susan OrrExecutive Officer
- Clarke AtwellExecutive Officer, Director
- Marc de GaridelDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- Proceeds to insiders
- $610K
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.3MraisedMar 2025 · 6 investors · BiotechnologyRule 506(b)
▶$3.3MraisedMar 2025 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kenneth HarrisonDirector
- Henry RathExecutive Officer
- Marc de GaridelDirector
- Meredith FisherDirector
- Susan OrrExecutive Officer
- Clarke AtwellExecutive Officer, Director
- Reza DanaDirector
- Offering amount
- $3.3M
- Amount sold
- $3.3M
- Proceeds to insiders
- $610K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJan 2024 · 3 investors · BiotechnologyRule 506(b)
▶$10MraisedJan 2024 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Henry RathExecutive Officer
- Kenneth HarrisonDirector
- Marc de GaridelDirector
- Meredith FisherDirector
- Reza DanaDirector
- Clarke AtwellExecutive Officer, Director
- Susan OrrExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Proceeds to insiders
- $1.8M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$44.5MraisedOct 2023 · 6 investors · BiotechnologyRule 506(b)
▶$44.5MraisedOct 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Meredith FisherDirector
- Marc de GaridelDirector
- Kenneth HarrisonDirector
- Clarke AtwellExecutive Officer, Director
- Reza DanaDirector
- Offering amount
- $44.5M
- Amount sold
- $44.5M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Claris Bio went on to found or lead other companies.
Frequently asked questions
- What does Claris Bio do?
- Claris Bio develops biologic therapies for sight-threatening eye diseases, with a current focus on bringing CSB-001, a novel treatment for patients with limbal stem cell deficiency, through clinical development and to market.
- Who founded Claris Bio?
- Claris Bio was founded by Clarke Atwell in 2018.
- Who are Claris Bio's investors?
- Claris Bio's investors include Catalio Capital Management, LP, RA Capital, Sofinnova Ventures, Catalio Capital Management, Novo Holdings, Samsara BioCapital.
- How much funding has Claris Bio raised?
- Claris Bio has disclosed $233.8M raised across 6 of its 8 known rounds.
- Where is Claris Bio headquartered?
- Claris Bio is headquartered in Jersey City, US.